Development of Proprietary Extraction & Purification Technologies


Development of Proprietary Extraction & Purification Technologies


Development of Proprietary Extraction & Purification Technologies

Pharmaceutical, branding and science concept -  Vitamin D and golden Omega 3 pills for healthy diet nutrition, fish oil food supplement pill capsules, healthcare and medicine as pharmacy background

Development of Proprietary Extraction & Purification Technologies


Supporting mental health and well-being through the extraction, biosynthesis and purification of high value compounds

Omind Science is a Canadian biotechnology company that aims, through its PRS™, Azimut™ and Azimut Pure™ platforms, to become a leader in the development of novel biomanufacturing platforms to produce pharmaceutical grade natural biopharma APIs and extraction and filtration technologies to advance the industrial efficiency of established production lines.

Inspired by nature and the richness of our marine ecosystem, we leverage the potential of plants and other organisms to cost-effectively produce, using bioreactors, biopharmaceutical and related natural compounds that address the unmet needs for mental health and well-being.

Our vision is to make mental health and well-being compounds available to those who need it by providing accessible science-driven natural compounds.


Development of the PRS™, Azimut™ and Azimut Pure™ platforms

Using a peroxide reduction system, currently under development, we will purify newly extracted and poor-quality or out-of-date fish oils (unfit for consumption), in order to improve their quality and purity as well as extend their shelf-life, without affecting their omega-3 fatty acid content. This could potentially represent substantial savings for the fish oil industry that currently sees waste losses between 10 and 20%.

Based on a novel approach soon to be proprietary, we use microalgae and other organisms as microbial cell-factories to produce, in bioreactors, psilocybin and other natural compounds as therapeutics agents to promote mental health and cognitive functions. The rationale is that these microorganisms have remarkable biotechnological potential to produce a range of bio-compounds such as pigments, lipids, polysaccharides, biopolymers, proteins, and vitamins when submitted to specific conditions.

When cultivated in bioreactors, they offer a potentially high productivity, lack of seasonality, a much higher controlled environment when compared to the production in their natural environment. Also, once this production process is implemented, significant cost reduction to biosynthesize the target molecules as well as improvements of quality control parameters are expected. Omind’s compounds will comply with pharmaceutical-grade standards.

Canada and the world are in the grips of a mental health crisis that ruins health, threatens lives and hurts economies.

Knowing the facts is the first step on the way to creating new hope.

  • From addiction to dementia to schizophrenia, approximately 1 billion people worldwide suffer from a mental disorder.
  • Mental disorders account for 30% of non-fatal disease burden worldwide and 10% of overall disease burden, including death and disability, thus imposing a heavy public health burden.

The economic burden of mental illness in Canada is estimated at over $50 billion per year. This includes health care costs, lost productivity, and reductions in health-related quality of life. The pharma industry is currently seeing a major shift away from anti-depressors and the research focused around this shift appears geared at using psychedelic compounds that are safer in nature.

Current treatments do not adequately address the complex challenges of mental illness. Fortunately, in recent years, clinical trials have begun for what could prove to be a renaissance for mental health care: the use of psychedelics.

Psychedelic drug-assisted psychotherapy is a novel approach to address the unmet medical needs in mental health.

The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Psilocybin, the active compound found in the so called “magic mushrooms”, is probably one of the best-known psychedelics along with ketamine and MDMA.

With its use being legally controlled since the early 70s, psychedelic research was very limited for a long time. Only recently psychedelic research has slowly made its reintroduction back into the paradigm of modern science and many clinical studies confirm the potential of psychedelics-assisted therapy as a promising adjunct to psychotherapy.

This new approach is gaining such momentum that renowned health centers, such as the John Hopkins University (USA), Harvard University (USA) and the Imperial College (UK), have in their Medicine department a dedicated Center for Psychedelic Research. Their research programs focus on the use of psychedelics for illnesses such as anxiety and depression.

Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike any treatments currently available. Not only do they produce sustained therapeutic effects following a single administration, but they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse disorder, and alcohol use disorder, among others.

The growing prevalence of mental depression, anxiety, stress and availability of off-label drugs propelled the demand of the psychedelic drugs market, particularly psilocybin-assisted psychotherapies, which may alleviate some of the challenges that face conventional psychiatric medicine.

In the 2nd quarter of 2019, more than US$ 320 million were invested into psychedelic neuropharmaceutical development, followed by an estimated US$ 100 million investment into various psychedelic research and clinical trials in the 3rd quarter of 2019.

Global psychedelic drugs market is expected to grow from $3.21 in 2021 to a value of $6.33 billion in 2026 with a CAGR of 14.5% during the forecast period as there is a large unmet need for treatment driving the adoption of psychedelic drugs.

For further information please contact [email protected]. 


OMind Innovations has access to a significant network at both provincial and federal levels, as well as with R&D institutions and private organizations.

Our partners have a successful track record of pure and applied research with
bioreactors, including those using microalgae, applied chemistry, as well as chemistry manufacturing control. In these partnership agreements, we can also benefit from research centre infrastructures, staff and in-house expertise, saving our team substantial expenses that would have been incurred otherwise.  Inversely, this represents a unique opportunity for creating tangible value.

Marine biotechnology, Regulatory, Industrial R&D and Health Canada licensed establishment
Bioreactors, New bio procedures and Engineering
Mass Spectrometry, Bioanalysis (ADME), Toxicology and In vivo models
Regulatory compliance and quality control


Administrative aspects, coordination



An executive in the field of applied sciences with 12 years of experience in leadership, strategic vision, budget management, project delivery, applied research and research funding management. He holds a Ph.D., a Master’s and a Bachelor’s degree in forestry, combining his applied knowledge from Brazil and from Canada.


Jean-Christophe Mellon, Ph.D

Organic chemistry, industrial scaling up


André Pichette, Ph.D

Organic chemistry, bioanalytical chemistry


Yves Lachance, Ph.D

Regulatory, OpDev, Product research


Jean Legault, Ph.D

Biological activities of products of natural origin


Samuel Godefroy, Ph.D

Former Director General of Health Canada’s Food Directorat. Former Vice Chair of the FAO/WHO Codex Alimentarius Commission. Full Professor of Food Risk Analysis and Regulatory Policies in the Department of Food Science, Laval University (Quebec).

Board Advisor

Dr. Valérie Tourjman, MD Psychiatry

Psychiatrist and researcher, Dr. Valérie Tourjman is Associate Clinical Professor in the Department of Psychiatry at the University of Montreal and Medical Head of the Anxiety and Mood Disorders Program at the Mental Health Institute of Montreal.


For further information please contact us


1500 Georgia Street West, Floor 13, Vancouver, British Columbia, V6G 2Z6, Canada

Contact Form Landing Page